Cypress Bioscience is a medical service provider that facilitates individualized patient care. The service provides its patients with therapeutic and personalized medical services in a variety of needs such as isolated areas of pain, rheumatology, and physical medicine and rehabilitation. It also addresses challenging disorders such as fibromyalgia and rheumatoid arthritis. Furthermore, the organization engages in the development of drugs such as Savella, a milnacipran HCI for the treatment of fibromyalgia, as well as Prosorba, a medical device for rheumatoid arthritis. Cypress Bioscience was founded in 1981 and is based in San Diego, California.

Ferring BV offers pharmaceutical products. It offers medicines in Gynaecology, Gastroenterology, Endocrinology and Urology. The company was founded in 1984 and is headquartered in Hoofddorp, Netherlands.

Sucampo GmbH, a subsidiary of Mallinckrodt Plc, is a Swiss company located in Zug that manufactures and distributes pharmaceuticals and health care products. It was founded by Ryuji Ueno and Sachiko Kuno. On December 29, 2010 Sucampo Pharmaceuticals, Inc., now a subsidiary of Mallinckrodt Plc acquired Sucampo GmbH for $120.00 million.

AOP Orphan Pharmaceuticals AG researches, develops, produces, and distributes drugs. It provides individual treatments for HematoOncology; Cardiology and Pulmonology; and Neurology and Metabolic Disorders. The company was founded by Rudolf S. Widmann in 1996 and is headquartered in Vienna, Austria.

DemeRx, Inc. provides biotechnology services. It focuses on drug addiction among patients coping with chronic pain. The company was founded by Deborah C. Mash on March 1, 2010 and is headquartered in Miami, FL.

Visioneering Technologies, Inc., headquartered in Alpharetta, Georgia, is an innovative new company that is dedicated to redefining vision. With a portfolio of technologies to address eye care issues such as presbyopia in adults and myopia correction in children, the company uses creative and differentiated design approaches to develop products that will ultimately enhance practitioner and patient experiences. VTI was founded by Dr. Richard A. Griffin, an optometrist, optical engineer and aerospace engineer who has spent 20 years developing VTI’s optical solutions. From Dr. Griffin's design, VTI holds fourteen issued patents worldwide that address the need for a treatment for presbyopia in the underdeveloped on-eye/in-eye categories. VTI brings together clinical, marketing, engineering, manufacturing and regulatory leaders from today's top vision care businesses. Together, these industry veterans bring the best thinking in eye care to design and bring to market new solutions for presbyopia, myopia and astigmatism.

Boehringer Ingelheim Animal Health USA, Inc. manufactures biological vaccines for animals. The firm specializes in pharmaceuticals for cattle, equine, pet, and swine. The company was founded by Albrecht Boehringer in 1885 and is headquartered in Duluth, GA.

Assertio is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia (diclofenac potassium for oral solution) for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor (diclofenac potassium) liquid-filled capsules for relief of mild to moderate acute pain, and Lazanda (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for Gralise, Cambia, Zipsor, and Lazanda.

Indena is the world’s leading company in the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and personal care industries.Indena, a privately owned Italian company, has around 800 employees (10% of them dedicated to full-time research) and has cultivation, manufacturing, and sales in more than 70 countries throughout the world.

Galderma Research & Development SNC discovers, develops, and markets therapeutic, corrective, and aesthetic solutions. The company is headquartered in Biot, France.

Pear Tree Pharmaceuticals, Inc. operates as a development stage company with interests in developing prescription products for women. It offers products that treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The company was founded by Stephen Charles Rocamboli, Fred H. Mermelstein, Janet Chollet and Martin J. Driscoll in July 2007 and is headquartered in Auburndale, MA.

MEDA Pharma is a company that provides healthcare services to people of high quality with safety. A medium-sized pharmaceutical company, Madaus GmbH belongs to the worldwide operating Meda Group. They manufacture pharmaceuticals as well as scientifically based health products such as medical devices, cosmetics, and dietary supplements. Its mission was to set new standards for health care, give 7 billion people access to high-quality medicine, and carry out research to address unmet healthcare needs.

Xili Technology (Beijing) Co., Ltd., established on 2015-05-05, Business scope includes technology development,technical consulting,Technical Services,Technology Promotion,technology transfer;data processing(Bank Card Center in Data Processing,PUEvalue in1.5Except for the above cloud computing data centers);selling computers,Software and Auxiliary Equipment,electronic product,communication equipment,Equipment,medical instrumentsIkind.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)